VANCOUVER, B.C., June 6, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided comments on recently presented data from a Phase I human clinical trial with ALN-VSP conducted by Alnylam Pharmaceuticals, Inc. ALN-VSP, an RNAi therapeutic for the treatment of liver cancers, utilizes Tekmira's LNP technology, the only RNAi delivery technology supporting multiple clinical candidates being advanced by Tekmira and its partners in several different disease indications.
